Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Balila
- Development stage
- Unknown
- Lead developer
- Jolly Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Balila is a 25mg diazoxide capsule formulation developed and marketed by Jolly Healthcare for the treatment of congenital hyperinsulinism. As a small molecule potassium channel opener, it specifically targets ATP-sensitive potassium (KATP) channels in pancreatic beta cells. By keeping these channels open, it inhibits the release of insulin, thereby helping to manage and maintain blood glucose levels in patients with excessive insulin secretion due to rare genetic disorders. It is administered orally and is considered a first-line pharmacological treatment for this condition.
- Brand names
- Balila
- Other names
- Diazoxide Capsules 25mgdiazoxide
02
Targets
KATP channel (ATP-sensitive potassium channel)
Beyond the preview
Go deeper on Balila.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Balila.